Our singular scientific and clinical goal at Zebra
is more effective and more efficient utilization of
the unparalleled diversity of chemical space locked
in combinatorial libraries of human antibody genes.
We are achieving this goal by exploiting in a new
platform the diversity of the 100 billion+ members
of an antibody library with a novel proprietary
screening technology that allows new biologic drugs
- AGONISTS or ANTAGONISTS - to be selected directly
for FUNCTION in human cell based assays.
Just as we all seem to know that no two snow flakes have the same crystal structure,
extensive studies have shown that no two Zebra's have an identical stripe pattern.
Hence our name Zebra Biologics.
Drug discovery is all about diversity of chemical space and efficient ways to find rare events - high affinity binding of a novel small molecule, peptide or antibody to a drug target. The combined small molecule libraries of all major pharmaceutical companies are in the range of 50-100 million compounds. The repertoire of antibodies in the standard humanized mouse widely used as a cumbersome in vivo tool for selecting novel antibody candidates for drug development is perhaps 100-500 million. A good combinatorial human antibody library boast 100 billion unique sequences and has the advantage of being exploitable in a test tube for drug discovery